Oculis Holding AG Reports CHF 5.2M Loss, Reelects Board Members at 2025 AGM

Oculis Holding AG held its 2025 Annual General Meeting on June 4, where shareholders approved all agenda items including the 2024 Annual Report and Financial Statements despite the company reporting a standalone loss of CHF 5,179,000 for 2024, contributing to an accumulated loss of CHF 46,577,000. Key board members including Anthony Rosenberg were re-elected, and PricewaterhouseCoopers SA was confirmed as Statutory Auditors, reflecting stability in leadership. Shareholders also approved compensation packages for the Board of Directors and Executive Committee, including fixed and equity-based remuneration, as well as conditional share capital intended to incentivize employees. In May 2025, Oculis completed the vesting and settlement of Restricted Stock Units for directors Anthony Rosenberg and Arshad Khanani, converting RSUs into actual shares as part of executive compensation. The company continues to focus on innovative treatments in ophthalmic and neuro-ophthalmic diseases, supported by experienced leadership and a solid institutional investor base. These developments underscore Oculis' ongoing commitment to governance, talent retention, and growth despite recent financial challenges.